Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track

Read more at globenewswire.com